Effects of an orally active non-peptide bradykinin B2 receptor antagonist, FR173657, on plasma exudation in rat carrageenin-induced pleurisy

British Journal of Pharmacology

Volumn 121, Issue 4, 1997, Pages 723-730

  Majima, Masataka ^a   Kawashima, Noriko ^a   Hiroshi, Ito ^a   Katori, Makoto ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antagonist; Bradykinin B2 receptor; Carrageenin induced pleurisy; Non peptide; Orally active; Plasma exudation

Indexed keywords

3 (6 ACETAMIDO 3 PYRIDYL) N [N [2,4 DICHLORO 3 [(2 METHYL 8 QUINOLINYL)OXYMETHYL]PHENYL] N METHYLAMINOCARBONYLMETHYL]ACRYLAMIDE; BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR; BROMELAIN; CARRAGEENAN; COMPOUND 48-80; HISTAMINE; ICATIBANT; KALLIKREIN INHIBITOR; MEPYRAMINE; METHYSERGIDE; SOYBEAN TRYPSIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG POTENCY; EXUDATE; INTRAPLEURAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLEURISY; PRIORITY JOURNAL; RAT;

ANIMALS; CARRAGEENAN; EXCIPIENTS; HYPOTENSION; MALE; PLEURAL EFFUSION; PLEURISY; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ;

EID: 0030919924     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701194     Document Type: Article

References (38)

1. 2 receptor antagonist, FR173657. Br. J. Pharmacol., 120, 617-624.
2. BHOOLA, K.D., FIGUEROA, C.D. & WORTHY, K. (1992). Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol. Rev., 44, 1-80.
3. BURCH, R.M., FARMER, S.G. & STEANKA, L.R. (1990). Bradykinin receptor antagonists. Med. Res. Rev., 10, 237-269.
4. CHERONIS, J.C., WHALLEY, E.T., NGUYEN, K.T., EUBANKS, S.R., ALLEN, L.G., DUGGAN, M.J., LOY, S.D., BONHAM, K.A. & BLODGETT, J.K. (1992). A new class of bradykinin antagonists: synthesis and in vitro activity of bissuccinimidoalkaline peptide dimers. J. Med. Chem., 35, 1563-1572.
5. 8]-bradykinin) in different in vivo animal models of inflammation. J. Pharmacol. Exp. Ther., 273, 1078-1084.
6. FERREIRA, S.H. & VANE, J.R. (1967). The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Br. J. Pharmacol., 30, 417-424.
7. 2 receptor antagonist WIN64338 in vivo and in vitro. Br. J. Pharmacol., 116, 3164-3168.
8. HESS, J.F., BORKOWSKI, J.A., YOUNG, G.S., STRADER, C.D. & RANSOM, R.W. (1992). Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem. Biophys. Res. Commun., 184, 260-268.
9. HOCK, F.J., WIRTH, K., ALBUS, U., LINZ, W., GERHARD, H.J., WIEMER, G., HENKE, S., BREIPOHL, G., KONIG, W., KNOLLE, J. & SCHOLKENS, B.A. (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol., 102, 769-773.
10. 4 in inflammatory models. Dermatologia, 179, 60-63.
11. KATORI, M., MAJIMA, M., ODI-ADOME, R., SUNSHARA, N. & UCHIDA, Y. (1989b). Evidence for the involvement of a plasma kallikrein-kinin system in the immediate hypotension produced by endotoxin in anaesthetized rats. Br. J. Pharmacol., 78, 1383-1391.
12. KATORI, M. & MAJIMA, M. (1996). Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn. J. Pharmacol., 70, 95-128.
13. KATORI, M., UCHIDA, Y., OH-ISHI, S., HARADA, Y., UENO, A. & TANAKA, K. (1979). Involvement of plasma kallikrein-kinin system in rat carrageenin-induced pleurisy. Eur. J. Rheumatol. Inflammation, 2, 217-219.
14. KAUKER, M.L., CROFTON, J.T., SHARE, L. & NASJELETTI, A. (1984). Role of vasopressin in regulation of renal kinin excretion in Long-Evans and diabetes insipidus rats. J. Clin. Invest., 73, 824-831.
15. LOWRY, O.H., ROSEBROUGH, N.T., FARR, A.L. & RANDALL, R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275.
16. MAJIMA, M. & KATORI, M. (1989). Degradation of Hageman factor by chymotrypsin-like protease released from rat mast cells during degranulation. Adv. Exp. Med. Biol., 247A, 485-487.
17. MAJIMA, M. & KATORI, M. (1995). Approaches to the development of novel antihypertensive drugs: crucial role of the renal kallikrein-kinin system. Trends Pharmacol. Sci., 16, 239-246.
18. MAJIMA, M., KATORI, M., OGINO, M., SAITO, M., SUGIMOTO, K., ADACHI, K., OHNO, T., SUNAHARA, N., KATOH, K., TATEMICHI, N. & TAKEI, Y. (1996a). Failure of endogenous blood kinin levels elevated by captopril to induce hypotension in normotensive and hypertensive rats: A study using a newly developed ELISA for kinin. Biomed. Res., 17, 15-25.
19. MAJIMA, M., MIZOGAMI, S., KURIBAYASHI, Y., KATORI, M. & OHISHI, S. (1994). Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension, 24, 111-119.
20. MAJIMA, M., NISHIYAMA, K., IGUCHI, Y., YAO, K., OGINO, M., OHNO, T., SUNAHARA, N., KATOH, K., TATEMICHI, N., TAKEI, Y. & KATORI, M. (1996b). Determination of bradykinin-(1 - 5) in inflammatory exudate by a new ELISA as a reliable indicator of bradykinin generation. Inflamm. Res., 45, 416-423.
21. MAJIMA, M., SUNAHARA, N., HARADA, Y. & KATORI, M. (1993). Detection of the degradation products of bradykinin by enzyme immunoassays as markers for the release of kinin in vivo. Biochem. Pharmacol., 45, 559-567.
22. MAJIMA, M., TANI, Y. & KATORI, M. (1987). Loss of the activity of human coagulation factor XII by a chymotrypsin-like protease activated in rat mast cells during degradation with compound 48/80. Thromb. Res., 46, 855-867.
23. 9-bradykinin by enzyme immunoassay - A useful parameter of plasma kinin release. Adv. Exp. Med. Biol., 247B, 535-540.
24. 1 bradykinin receptor. J. Biol. Chem., 269, 21583-21586.
25. OH-ISHI, S. & KATORI, M. (1979). Fluorometric assay method for plasma prekallikrein using peptidylmethyl-coumarylamide as a substrate. Thromb. Res., 14, 551-559.
26. OH-ISHI, S., UCHlDA, Y., UENO, A. & KATORI, M. (1979). Bromelain, a thiolprotease from pineapple stem, depletes high-molecular-weight kininogen by activation of Hageman factor (factor XII). Throm. Res., 14, 665-672.
27. REGOLI, D. & BARABE, J. (1980). Pharmacology of bradykinin and related peptides. Pharmacol. Rev., 32, 1-46.
28. 2 receptor. J. Med. Chem., 36, 2583-2584.
29. 2 receptor antagonist. Proc. Natl. Acad. Sci. U.S.A., 91, 4693-4697.
30. SCHWARTZ, L.B. & AUSTEN, K.F. (1984). Structure and function of the chemical mediators of mast cells. Prog. Allergy, 34, 271-321.
31. STEWART, J.M. (1995). Bradykinin antagonist: development and applications. Biopolymers, 37, 143-155.
32. TANAKA, K., UENO, A. & KATORI, M. (1986). Roles of leukotrienes in two rat allergic inflammatory models: IgE-mediated and IgG-antigen complex-induced pleurisies. Prostaglandins, 31, 1099-1116.
33. TISSOT, M., REGOLI, D. & GIROUD, J.P. (1985). Bradykinin levels in inflammatory exudates. Inflammation, 9, 419-424.
34. UCHIDA, Y. & KATORI, M. (1986). Independent consumption of high and low molecular weight kininogens in vivo. Adv. Exp. Med. Biol., 198, 113-117.
35. UCHIDA, Y., MAJIMA, M. & KATORI, M. (1986). A method of determination of human plasma HMW and LMW kininogen levels by bradykinin enzyme immunoassay. Pharmacol. Res. Commun., 18, 831-846.
36. UCHIDA, Y., TANAKA, K., HARADA, Y., UENO, A. & KATORI, M. (1983). Activation of plasma kallikrein-kinin system and its significant role in rat carrageenin-induced pleurisy. Inflammation, 7, 121-131.
37. VAVREK, R. & STEWART, J.M. (1985). Competitive antagonists of bradykinin. Peptides, 6, 161-164.
38. WIRTH, K., HOCK, F.J., ALBUS, U., LINZ, W., ALPERMANN, H.G., ANAGNOSTOPOULOS, H., HENKE, S., BREIPOHL, G., KONIG, W., KNOLLE, J. & SCHOLKENS, B.A. (1991). Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br. J. Pharmacol., 102, 174-711.